Notes to Editors:
International Biotechnology Trust plc
http://www.internationalbiotrust.com
International Biotechnology Trust plc (IBT) was launched to take advantage of the investment
opportunities arising in mid-stage life science companies, with emphasis on investing in
relatively few companies, and involving a close working relationship with investee companies
through the provision of strategic management support and sector expertise.
Key Data
· Founded in 1994
· Net asset value £108.97 million at 7 August 2001
· NAV per share of 224.14p as at 7 August 2001
· Listed on London Stock Exchange (IBT.L)
· Advised by Schroder Ventures Life Sciences Advisers (UK) Limited and managed by
Schroders Investment Management Ltd
Schroder Ventures Life Sciences
http://
www.svlifesciences.com
Schroder Ventures* has been investing in life science companies since 1983. Schroder
Ventures Life Sciences** (SVLS) was established in 1994, as the dedicated life sciences arm
of Schroder Ventures. SVLS has established itself as a leading international life sciences
investor with a team of 18 dedicated professionals in London and Boston. SVLS advises
funds of approximately $600m and has invested in more than 100 life sciences companies
world-wide.
*Schroder Ventures is a leading international private equity group advising 25 funds world-
wide with committed capital totalling $7 billion. To date, Schroder Ventures' funds have
invested in over 400 companies in a mixture of early stage transactions and buy-outs.
** Schroder Ventures Life Sciences Advisers (UK) Limited is regulated by IMRO.
Discovery Therapeutics, Inc (DTI)
http://www.discoverytherapeutics.com
DTI was formed in 1994 to commercialise small-molecule drug candidates that act selectively
on subtypes of dopamine and adenosine receptors. It began operations by acquiring the
pharmaceutical research programmes of Whitby Research Inc, a wholly-owned subsidiary for
Ethyl Corp of Richmond, VA. In 1999, the company acquired Renalogics in order to
strategically position itself to develop and commercialise new products for kidney disease. In
2000, DTI licensed drug candidates for kidney inflammation that are in late stage of clinical
development.
